23
Participants
Start Date
November 1, 2002
Primary Completion Date
April 10, 2006
Study Completion Date
April 10, 2006
Lonafarnib (SCH66336)
"Participants in CHRONIC PHASE receive Gleevec 400 mg by mouth every day, and SCH66336 100 mg by mouth twice a day.~Participants in ACCELERATED OR BLASTIC PHASE receive SCH66336 100 mg by mouth twice a day.~Participants in ACCELERATED OR BLASTIC PHASE receive SCH66336 100 mg by mouth twice a day."
Imatinib Mesylate (Gleevec)
"Participants in CHRONIC PHASE receive Gleevec 400 mg by mouth every day.~Participants in ACCELERATED OR BLASTIC PHASE receive Gleevec 600 mg by mouth every day."
M.D. Anderson Cancer Center, Houston
M.D. Anderson Cancer Center
OTHER